IT   EN

Ultimi tweet

Janssen to highlight data from broad rheumatology portfolio at the 2018 Annual meeting of the American College of Rheumatology #ACR18

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will be presenting results from 13 abstracts across the company’s rheumatology portfolio and pipeline products during the 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting taking place in Chicago, IL, from 19–24 October.

New results from a Phase 2 trial evaluating STELARA®* (ustekinumab) in patients with active systemic lupus erythematosus (SLE) treated through one year will be presented in a plenary presentation on Tuesday, 23 October, with additional data from that study also featured as an oral presentation. These results highlight the depth and breadth of the Janssen rheumatology portfolio and advance the understanding of the safety and efficacy of ustekinumab and TREMFYA®** (guselkumab) across multiple immune-mediated diseases, including SLE, moderate-to-severe plaque psoriasis (PsO) and active psoriatic arthritis (PsA).

“The broad range of data being presented at this year’s annual meeting spans the spectrum from clinical investigational studies to real world evidence about our marketed products, such as ustekinumab and guselkumab, in clinical practice settings,” said Jaime Oliver Vigueras, Europe, Middle East and Africa Immunology Therapeutic Area Lead, Janssen-Cilag AG.

“These studies build on our longstanding heritage of innovation in rheumatology and help further our understanding of potential new treatment pathways in diseases like lupus, where there is significant unmet patient need.”

Commenta questo articolo:

*
Il tuo indirizzo email non sarà visibile agli altri utenti.
Il commento sarà pubblicato solo previa approvazione del webmaster.